One is FSCN1 as a circulating marker in PCa and the other to use FSCN1 mRNA data from publicly available transcriptomics data analysis to support the previously inconclusive statements regarding FSCN1 expression based on immunohistochemical data. This evidence concerns the gene FSCN1 and posterior cortical atrophy.